Chemotherapy-induced peripheral neuropathy and rehabilitation: A review

Zhang, Shangming

doi:10.1053/j.seminoncol.2021.09.004

Cited by 42 publications

(30 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A systematic review and meta-analysis showed a CIPN prevalence of around 2/3 within the first month of the end of chemotherapy with a progressive decrease until 1/3 at 6 months or later ( Seretny et al, 2014 ). Unfortunately, there are no clinically relevant approaches for preventing CIPN and/or treating established CIPN, except for the limited effect described for duloxetine in the treatment of CIPN pain ( Smith et al, 2013 ; Loprinzi et al, 2020 ; Bae et al, 2021 ; Zhang, 2021 ). The development and evaluation of novel strategies to mitigate and manage the chronic side effects of cancer therapy (CIPN included) have been established as urgent areas of research by the American Society of Clinical Oncology (ASCO) ( Markham et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Long-term improvement by ozone treatment in chronic pain secondary to chemotherapy-induced peripheral neuropathy: A preliminary report

et al. 2022

View full text Add to dashboard Cite

Background: Pain secondary to chemotherapy-induced peripheral neuropathy (CIPN) can limit the administration of chemotherapy, cancer-treatment outcomes, and the quality of life of patients. Oxidative stress and inflammation are some of the key mechanisms involved in CIPN. Successful treatments for CIPN are limited. This report shows our preliminary experience using ozone treatment as a modulator of oxidative stress in chronic pain secondary to CIPN.Methods: Ozone treatment, by rectal insufflation, was administered in seven patients suffering from pain secondary to grade II or III CIPN. Pain was assessed by the visual analog scale (VAS).Results: All patients, except one, showed clinically relevant pain improvement. Median pain score according to the VAS was 7 (range: 5–8) before ozone treatment, 4 (range: 2–6) at the end of ozone treatment (p = 0.004), 5.5 (range: 1.8–6.3) 3 months after the end of ozone treatment (p = 0.008), and 6 (range: 2.6–6.6) 6 months after the end of ozone treatment (p = 0.008). The toxicity grade, according to the Common Terminology Criteria for Adverse Events (CTCAE v.5.0), improved in half of the patients.Conclusion: This report shows that most patients obtained clinically relevant and long-lasting improvement in chronic pain secondary to CIPN after treatment with ozone. These observed effects merit further research and support our ongoing randomized clinical trial (NCT04299893).

show abstract

Section: Introductionmentioning

confidence: 99%

Long-term improvement by ozone treatment in chronic pain secondary to chemotherapy-induced peripheral neuropathy: A preliminary report

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The effect of SH003 in chemotherapy-induced neuropathic pain has been demonstrated in docetaxel-induced mechanical allodynia [54]; however, its effect on paclitaxel has never been investigated. Although both docetaxel and paclitaxel are taxanes, paclitaxel has been reported to be more neurotoxic than docetaxel [48]. Furthermore, in a previous study [54], the effect of SH003 components was not investigated, whereas in this study, the effect of each component was assessed accordingly.…”

Section: Discussionmentioning

confidence: 91%

“…Paclitaxel-induced neuropathic pain manifests as cold and mechanical allodynia in animal models [23,41]. As part of its pathological mechanism, it is known that accumulated paclitaxel in dorsal-root ganglia causes axon degeneration and demyelination of large-and small-fiber sensory neurons [48,49]. As a result, sensory input from damaged peripheral neurons can induce hyperactivation of spinal neurons, which finally develops into central sensitization [11,23].…”

Section: Discussionmentioning

confidence: 99%

Analgesic Effect of SH003 and Trichosanthes kirilowii Maximowicz in Paclitaxel-Induced Neuropathic Pain in Mice

Lee

Kim

et al. 2022

CIMB

View full text Add to dashboard Cite

Pacliatxel is a taxol-based chemotherapeutic drug that is widely used to treat cancer. However, it can also induce peripheral neuropathy, which limits its use. Although several drugs are prescribed to attenuate neuropathies, no optimal treatment is available. Thus, in our study, we analyzed whether SH003 and its sub-components could alleviate paclitaxel-induced neuropathic pain. Multiple paclitaxel injections (cumulative dose 8 mg/kg, i.p.) induced cold and mechanical allodynia from day 10 to day 21 after the first injection in mice. Oral administration of SH003, an herbal mixture extract of Astragalus membranaceus, Angelica gigas, and Trichosantheskirilowii Maximowicz (Tk), dose-dependently attenuated both allodynia. However, when administered separately only Tk decreased both allodynia. The effect of Tk was shown to be mediated by the spinal noradrenergic system as intrathecal pretreatment with α1- and α2-adrenergic-receptor antagonists (prazosin and idazoxan), but not 5-HT1/2, and 5-HT3-receptor antagonists (methysergide and MDL-72222) blocked the effect of Tk. The spinal noradrenaline levels were also upregulated. Among the phytochemicals of Tk, cucurbitacin D was shown to play a major role, as 0.025 mg/kg (i.p.) of cucurbitacin D alleviated allodynia similar to 500 mg/kg of SH003. These results suggest that Tk should be considered when treating paclitaxel-induced neuropathic pain.

show abstract

“…As mentioned above, chemotherapy causes severe side effects. Chemotherapy-induced peripheral neuropathy (CIPN) is one of the painful side effects characterized by damage to peripheral neurons [ 54 ]. Cancer patients who receive docetaxel experience acute pain syndrome [ 55 , 56 ].…”

Section: Current Advances Of Sh003 In Tumor Suppressionmentioning

confidence: 99%

State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent

Lee

Youn

Choi

et al. 2022

Cancers

View full text Add to dashboard Cite

Cancer ranks as the first leading cause of death globally. Despite the various types of cancer treatments, negative aspects of the treatments, such as side effects and drug resistance, have been a continuous dilemma for patients. Thus, natural compounds and herbal medicines have earned profound interest as chemopreventive agents for reducing burden for patients. SH003, a novel herbal medicine containing Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii, showed the potential to act as an anticancer agent in previous research studies. A narrative review was conducted to present the significant highlights of the total 15 SH003 studies from the past nine years. SH003 has shown positive results in both in vivo and vitro studies against various types of cancer cells; furthermore, the first clinical trial was performed to identify the maximum tolerated dose among solid cancer patients. So far, the potential of SH003 as a chemotherapeutic agent has been well-documented in research studies; continuous work on SH003’s efficacy and safety is required to facilitate better cancer patient care but is part of the knowledge needed to understand whether SH003 has the potential to become a pharmaceutical.

show abstract

Chemotherapy-induced peripheral neuropathy and rehabilitation: A review

Cited by 42 publications

References 100 publications

Long-term improvement by ozone treatment in chronic pain secondary to chemotherapy-induced peripheral neuropathy: A preliminary report

Long-term improvement by ozone treatment in chronic pain secondary to chemotherapy-induced peripheral neuropathy: A preliminary report

Analgesic Effect of SH003 and Trichosanthes kirilowii Maximowicz in Paclitaxel-Induced Neuropathic Pain in Mice

State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent

Contact Info

Product

Resources

About